Market Overview

USPTO Withdraws Sequenom Patent No. 8,340,916

Related SQNM
Sequenom To Explore The Clinical Utility Of A Novel Liquid Biopsy Assay In Melanoma Patients In Collaboration With University Of Colorado Denver
Sequenom Enters Clinical Collaboration With Seoul National University Hospital

Sequenom (NASDAQ: SQNM) announced Friday that the U.S. Patent and Trademark Office has withdrawn the issuance of U.S. Patent No. 8,340,916. Sequenom has been informed by the Patent and Trademark Office that issuance was withdrawn in connection with an anticipated patent interference proceeding between parties with pending patent applications or issued patents directed to similar subject matter. 

Sequenom had previously been notified that the patent would issue on December 25, 2012, with claims to novel methods for detecting fetal aneuploidy using massively parallel sequencing. The patent is entitled Diagnosing Fetal Chromosomal Aneuploidy Using Massively Parallel Genomic Sequencing and was invented by Drs. Dennis Lo, Rossa Chiu and Alan Chan of the Chinese University of Hong Kong. Sequenom has exclusive rights to this patent.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at to which Sequenom

See full press release

Posted-In: Earnings News Guidance Management


Related Articles (SQNM)

View Comments and Join the Discussion!

Get Benzinga's Newsletters